Finite Mixture Models, a Flexible Alternative to Standard Modeling Techniques for Extrapolated Mean Survival Times Needed for Cost-Effectiveness Analyses
Cislo, Paul R., Emir, Birol, Cabrera, Javier, Li, Benjamin, Alemayehu, Demissie
Published in Value in health (01.11.2021)
Published in Value in health (01.11.2021)
Get full text
Journal Article
Comparing g-computation, propensity score-based weighting, and targeted maximum likelihood estimation for analyzing externally controlled trials with both measured and unmeasured confounders: a simulation study
Ren, Jinma, Cislo, Paul, Cappelleri, Joseph C, Hlavacek, Patrick, DiBonaventura, Marco
Published in BMC medical research methodology (17.01.2023)
Published in BMC medical research methodology (17.01.2023)
Get full text
Journal Article
Meaningful within-patient change for clinical outcome assessments: model-based approach versus cumulative distribution functions
Ren, Jinma, Bushmakin, Andrew G, Cislo, Paul R, Abraham, Lucy, Cappelleri, Joseph C, Dworkin, Robert H, Farrar, John T
Published in Journal of biopharmaceutical statistics (20.11.2023)
Published in Journal of biopharmaceutical statistics (20.11.2023)
Get full text
Journal Article
Climate and Tick Seasonality Are Predictors of Borrelia burgdorferi Genotype Distribution
Gatewood, Anne G, Liebman, Kelly A, Vourc'h, Gwenaël, Bunikis, Jonas, Hamer, Sarah A, Cortinas, Roberto, Melton, Forrest, Cislo, Paul, Kitron, Uriel, Tsao, Jean, Barbour, Alan G, Fish, Durland, Diuk-Wasser, Maria A
Published in Applied and Environmental Microbiology (01.04.2009)
Published in Applied and Environmental Microbiology (01.04.2009)
Get full text
Journal Article
Estimated net benefit of avelumab (AVE) + best supportive care (BSC) vs BSC alone for patients (pts) with advanced urothelial carcinoma (aUC) using a quality-adjusted time without cancer symptoms or toxicity (Q-TWiST) analysis
Powles, Thomas, Cislo, Paul, Kirker, Melissa, Chang, Jane, Gharibian, Norbek, Thompson, Allison, Costa, Nuno, Grivas, Petros
Published in Journal of clinical oncology (01.06.2023)
Published in Journal of clinical oncology (01.06.2023)
Get full text
Journal Article
Reliability, validity, and clinically important differences (CIDs) on the NCCN/FACT Bladder Symptom Index (NFBISI-18) among individuals with locally advanced or metastatic urothelial cancer (UC)
Peipert, John, Chang, Jane, Li, Si, Di Pietro, Alessandra, Cislo, Paul, Cappelleri, Joseph C, Cella, David
Published in Journal of clinical oncology (20.02.2021)
Published in Journal of clinical oncology (20.02.2021)
Get full text
Journal Article
Reliability, validity, and change thresholds of the NCCN/FACT Bladder Symptom Index (NFBlSI‐18) in patients with advanced urothelial cancer
Peipert, John D., Chang, Jane, Li, Si, Pietro, Alessandra, Cislo, Paul, Cappelleri, Joseph C., Cella, David
Published in Cancer (01.01.2024)
Published in Cancer (01.01.2024)
Get full text
Journal Article
Long-term safety of avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC) in the JAVELIN Bladder 100 trial
Bellmunt, Joaquim, Aragon-Ching, Jeanny B., Climent, Miguel Ángel, Sridhar, Srikala S., Powles, Thomas, Cislo, Paul, Michelon, Elisabete, Di Pietro, Alessandra, Grivas, Petros
Published in Journal of clinical oncology (01.06.2023)
Published in Journal of clinical oncology (01.06.2023)
Get full text
Journal Article
Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma
Grivas, Petros, Kopyltsov, Evgeny, Su, Po-Jung, Parnis, Francis X., Park, Se Hoon, Yamamoto, Yoshiaki, Fong, Peter C., Tournigand, Christophe, Climent Duran, Miguel A., Bamias, Aristotelis, Caserta, Claudia, Chang, Jane, Cislo, Paul, di Pietro, Alessandra, Wang, Jing, Powles, Thomas
Published in European urology (01.04.2023)
Published in European urology (01.04.2023)
Get full text
Journal Article
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy
Sridhar, Srikala S., Powles, Thomas, Gupta, Shilpa, Climent, Miguel Ángel, Aragon-Ching, Jeanny B., Sternberg, Cora N., Cislo, Paul, Costa, Nuno, Di Pietro, Alessandra, Bellmunt, Joaquim, Grivas, Petros
Published in Journal of clinical oncology (20.02.2023)
Published in Journal of clinical oncology (20.02.2023)
Get full text
Journal Article
PD38-02 AVELUMAB FIRST-LINE MAINTENANCE FOR ADVANCED UROTHELIAL CARCINOMA: LONG-TERM OUTCOMES FROM JAVELIN BLADDER 100 IN SUBGROUPS DEFINED BY FIRST-LINE CHEMOTHERAPY REGIMEN AND ANALYSIS OF OVERALL SURVIVAL FROM START OF FIRST-LINE CHEMOTHERAPY
Sridhar, Srikala S., Powles, Thomas, Gupta, Shilpa, Climent Duran, Miguel A., Aragon-Ching, Jeanny B., Sternberg, Cora N., Cislo, Paul, Costa, Nuno, di Pietro, Alessandra, Bellmunt, Joaquim, Grivas, Petros
Published in The Journal of urology (01.05.2024)
Published in The Journal of urology (01.05.2024)
Get full text
Journal Article
Human Risk of Infection with Borrelia burgdorferi, the Lyme Disease Agent, in Eastern United States
DIUK-WASSER, Maria A, GATEWOOD HOEN, Anne, TSAO, Jean I, BUNIKIS, Jonas, BARBOUR, Alan G, KITRON, Uriel, PIESMAN, Joseph, FISH, Durland, CISLO, Paul, BRINKERHOFF, Robert, HAMER, Sarah A, ROWLAND, Michelle, CORTINAS, Roberto, VOURC'H, Gwenael, MELTON, Forrest, HICKLING, Graham J
Published in The American journal of tropical medicine and hygiene (01.02.2012)
Published in The American journal of tropical medicine and hygiene (01.02.2012)
Get full text
Journal Article
Patient-reported outcomes (PROs) with talazoparib (TALA) plus enzalutamide (ENZA) vs. placebo (PBO) plus ENZA in men with metastatic castration-resistant prostate cancer (mCRPC): Subgroup analysis of patients with novel hormonal therapy (NHT) pretreatment in the TALAPRO-2 study
De Giorgi, Ugo, Azad, Arun, Fizazi, Karim, Matsubara, Nobuaki, Saad, Fred, Joung, Jae Young, Fong, Peter C.C., Jones, Robert J., Zschaebitz, Stefanie, Oldenburg, Jan, Shore, Neal D., Dunshee, Curtis, Carles, Joan, Fay, Andre P., Cislo, Paul, Kirker, Melissa, Healy, Cynthia G., Niyazov, Alexander, Agarwal, Neeraj
Published in Journal of clinical oncology (01.02.2024)
Published in Journal of clinical oncology (01.02.2024)
Get full text
Journal Article
Patient reported outcomes (PROs) among patients with metastatic castration-resistant prostate cancer (mCRPC) by homologous recombination repair mutations (HRRm) gene clusters: Findings from the phase 3 TALAPRO-2 study cohort 2
Fizazi, Karim, Shore, Neal D., Fong, Peter C.C., Azad, Arun, Matsubara, Nobuaki, Saad, Fred, De Giorgi, Ugo, Joung, Jae Young, Jones, Robert J., Zschaebitz, Stefanie, Oldenburg, Jan, Dunshee, Curtis, Carles, Joan, Fay, Andre P., Cislo, Paul, Kirker, Melissa, Healy, Cynthia G., Niyazov, Alexander, Agarwal, Neeraj
Published in Journal of clinical oncology (01.02.2024)
Published in Journal of clinical oncology (01.02.2024)
Get full text
Journal Article
Patient-reported outcomes (PROs) among men receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC): Results from a phase 3 study (TALAPRO-2)
Agarwal, Neeraj, Azad, Arun, Matsubara, Nobuaki, Saad, Fred, De Giorgi, Ugo, Joung, Jae Young, Fong, Peter C.C., Jones, Robert J., Zschaebitz, Stefanie, Oldenburg, Jan, Shore, Neal D., Dunshee, Curtis, Carles, Joan, Fay, Andre P., Cislo, Paul, Chang, Jane, Healy, Cynthia G., Niyazov, Alexander, Fizazi, Karim
Published in Journal of clinical oncology (01.06.2023)
Published in Journal of clinical oncology (01.06.2023)
Get full text
Journal Article